1-{2-Cyclopropyl-4-fluoro-5-[5-fluoro-4-(1,2,2,6,6-pentamethyl-piperidin-4-ylamino)-pyrimidin-2-ylamino]-phenyl}-4-methyl-1,4-dihydro-tetrazol-5-one | 1309831-19-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-{2-Cyclopropyl-4-fluoro-5-[5-fluoro-4-(1,2,2,6,6-pentamethyl-piperidin-4-ylamino)-pyrimidin-2-ylamino]-phenyl}-4-methyl-1,4-dihydro-tetrazol-5-one
• 英文别名: N2-{4-cyclopropyl-6-fluoro-3-[4-methyl-1,2,3,4-tetrazol-5-one-1-yl]phenyl}-5-fluoro-N4-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,4-pyrimidinediamine；1-[2-Cyclopropyl-4-fluoro-5-[[5-fluoro-4-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]pyrimidin-2-yl]amino]phenyl]-4-methyltetrazol-5-one
• CAS: 1309831-19-3
• 化学式: C₂₅H₃₃F₂N₉O
• 分子量: 513.594
• InChiKey: MJAXMBPQWZSTMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  2-溴-4-氟苯甲酰氯 在 palladium diacetate 、 三环己基膦 盐酸 、 tin(II) chloride dihdyrate 、 叠氮基三甲基硅烷 、 硫酸 、 硝酸 、 potassium carbonate 、 caesium carbonate 、 对甲苯磺酸 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 反应 120.67h， 生成 1-{2-Cyclopropyl-4-fluoro-5-[5-fluoro-4-(1,2,2,6,6-pentamethyl-piperidin-4-ylamino)-pyrimidin-2-ylamino]-phenyl}-4-methyl-1,4-dihydro-tetrazol-5-one
  参考文献：
  名称：

  PROTEIN KINASE C INHIBITORS AND USES THEREOF

  摘要：

  这项披露涉及作为蛋白激酶C（PKC）抑制剂有用的化合物，因此对于治疗通过PKC活性介导或维持的各种疾病和疾病非常有用。这项披露还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。

  公开号：

  US20110130415A1

文献信息

• TETRAZOLONES AS PROTEIN KINASE C INHIBITORS AND USES THEREOF
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP2507227B1

  公开（公告）日：2014-10-08
• Protein Kinase C Inhibitors and Uses Thereof
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170152246A1

  公开（公告）日：2017-06-01

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
• US9732070B2
  申请人：——

  公开号：US9732070B2

  公开（公告）日：2017-08-15
• [EN] PROTEIN KINASE C INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE C ET LEURS UTILISATIONS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2011068898A1

  公开（公告）日：2011-06-09

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseThis disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.ases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
• PROTEIN KINASE C INHIBITORS AND USES THEREOF
  申请人：Singh Rajinder

  公开号：US20110130415A1

  公开（公告）日：2011-06-02

  This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  这项披露涉及作为蛋白激酶C（PKC）抑制剂有用的化合物，因此对于治疗通过PKC活性介导或维持的各种疾病和疾病非常有用。这项披露还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。